ARTICLE | Emerging Company Profile

Nutcracker: RNA design, delivery and manufacturing under one roof

Leveraging an Arch-led $167 million series C round, Nutcracker’s RNA-based therapy for HPV-driven cancers is heading to the clinic 

October 28, 2022 9:37 PM UTC

Nutcracker is developing an RNA platform it hopes will solve three challenges with the therapeutic modality: sequence design, delivery and manufacturing.

Nutcracker Therapeutics Inc. launched in 2017 to efficiently create RNA. But CBO Geoff Nosrati told BioCentury it learned that “you need to do so much more than just solve the manufacturing” to be an RNA company, including optimizing sequence design and delivery chemistry. ...